logo







Home>Companies>Design-therapeutics


Design therapeutics

Design therapeutics



Design Therapeutics is a biopharmaceutical company focused on the research and development of GeneTACTM molecules, which are innovative small-molecule therapies aimed at modifying diseases linked to inherited nucleotide repeat expansion mutations.
Sign up today to get real-time market insights on Design therapeutics and hundreds of other pre-IPO companies



Design therapeutics Overview

Carlsbad, CA, United States
Biotech
https://www.designtx.com



Design therapeutics Live Market Data

$00000000
$00000000




Design therapeutics Funding Rounds



RoundDateAmount RaisedValuationInvestorsSources
IPO3/26/2021
Series B1/1/2021
Series A3/6/2020
Accelerator/Incubator6/3/2019




Design therapeutics Investors



InvestorInvestment RoundsLead PartnerInitial InvestmentOther Notable Investments
BlackRock (NYS: BLK)Series BSeries B (2021-01-01)
Janus Henderson Investors (NYS: JHG)Series BSeries B (2021-01-01)
T. Rowe Price Group (NAS: TROW)Series BSeries B (2021-01-01)
Wellington ManagementSeries BSeries B (2021-01-01)




Design therapeutics 409a Valuations



DatePrice per shareEst. ValuationFilling
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Sign up to access Design therapeutics data




Design therapeutics Filings



TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign up to access Design therapeutics data




Latest Design therapeutics News







Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


DisclaimerAll investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.